Shares of Hologic Inc. (NASDAQ:HOLX) saw unusually-strong trading volume on Thursday . Approximately 4,891,649 shares changed hands during mid-day trading, an increase of 61% from the previous session’s volume of 3,035,463 shares.The stock last traded at $36.45 and had previously closed at $36.82.

A number of analysts have recently weighed in on HOLX shares. Goldman Sachs Group Inc. boosted their target price on shares of Hologic to $47.00 in a report on Wednesday, March 23rd. Bank of America Corp. restated a “buy” rating and issued a $46.00 target price on shares of Hologic in a report on Monday, March 28th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Thursday, April 28th. Leerink Swann restated a “buy” rating on shares of Hologic in a report on Thursday, April 28th. Finally, Canaccord Genuity restated a “buy” rating on shares of Hologic in a report on Thursday, April 28th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $43.00.

The firm has a market capitalization of $10.16 billion and a PE ratio of 51.41. The firm has a 50 day moving average of $34.77 and a 200 day moving average of $34.86.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, April 27th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. During the same quarter in the prior year, the firm earned $0.41 earnings per share. The business earned $693.30 million during the quarter, compared to analysts’ expectations of $686.82 million. Hologic’s quarterly revenue was up 5.8% on a year-over-year basis. Equities analysts expect that Hologic Inc. will post $1.91 earnings per share for the current fiscal year.

In related news, Director Lawrence M. Levy sold 17,794 shares of the business’s stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $34.41, for a total value of $612,291.54. Following the sale, the director now directly owns 23,257 shares in the company, valued at approximately $800,273.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Peter J. Valenti III sold 10,022 shares of the business’s stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $33.83, for a total transaction of $339,044.26. Following the completion of the sale, the insider now owns 9,023 shares in the company, valued at $305,248.09. The disclosure for this sale can be found here.

Several large investors have added to or reduced their stakes in HOLX. Whalerock Point Partners LLC raised its stake in Hologic by 3.6% in the fourth quarter. Whalerock Point Partners LLC now owns 27,950 shares of the company’s stock valued at $1,081,000 after buying an additional 960 shares in the last quarter. ProShare Advisors LLC raised its position in Hologic by 11.0% in the fourth quarter. ProShare Advisors LLC now owns 31,895 shares of the company’s stock worth $1,234,000 after buying an additional 3,166 shares during the period. Ameritas Investment Partners Inc. raised its position in Hologic by 1.5% in the fourth quarter. Ameritas Investment Partners Inc. now owns 37,147 shares of the company’s stock worth $1,437,000 after buying an additional 533 shares during the period. Advisors Asset Management Inc. raised its position in Hologic by 2.7% in the fourth quarter. Advisors Asset Management Inc. now owns 50,447 shares of the company’s stock worth $1,952,000 after buying an additional 1,315 shares during the period. Finally, GSA Capital Partners LLP raised its position in Hologic by 61.7% in the fourth quarter. GSA Capital Partners LLP now owns 51,476 shares of the company’s stock worth $1,992,000 after buying an additional 19,632 shares during the period.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.